

1053
39

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ruth Gjerset *et al.*

APPLICATION No.: 08/335,461

FILED: November 7, 1994

FOR: ENHANCING THE SENSITIVITY OF TUMOR CELLS
TO THERAPIES

EXAMINER: CHRISTOPHER LOW

ART UNIT: 1653

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is being deposited this 1st day of April, 2003, with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents and Trademarks, Washington, D.C. 20231.

Deborah Muench
DEBORAH MUENCH

SUBMISSION OF REFERENCES

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

On March 14, 2003, we filed a Supplemental Information Disclosure Statement along with the Supplemental Form PTO-1449 and cited references.

The following references were cited in the Supplemental PTO-1449 but were inadvertently not enclosed with the Supplemental PTO-1449, but are enclosed herewith:

- C15 CONROY, "New Gene Therapy Cleared for Use Against Lung Cancer," *Biotech Daily*, pp. 3-4, September 18, 1992.
- C41 GOBE *et al.*, "Cell Death By Apoptosis Following X-Irradiation of the Foetal and Neonatal Rat Kidney," *Intl. J. Radiat. Biol.*, 54:567-576, 1988.
- C65 IJIRI, "Apoptosis (cell death) Induced in Mouse Bowel by 1,2-Dimethylhydrazine, Methylazoxymethanol Acetate and γ -Rays," *Cancer Research*, 49:6342-6346, 1989.
- C75 KHOKHA, Rama *et al.*, "Antisense RNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss3T3 Cells," *Science*, 243:947-950, 1989.
- C87 LESOON-WOOD *et al.*, "Systemic Gene Therapy with a Liposome-p53 Complex Reduces the Growth and Metastases of a Malignant Human Breast Cancer in Nude Mice," *Proc. Annu. Meet. Am. Assoc. Cancer Res.*, Vol. 36, pp. A2509, 1995.
- ? C100 McGRATH *et al.*, "Tumor-Specific Antisense Oligonucleotides for Controlling Cancer," Abstract No. 114:5578n, *Chemical Abstracts*, 114(7):68, 1991.

C121 ~~PAUL~~ *et al.*, "The Synthesis of XTT: a New Tetrazolium Reagent that is Bioreducible to a Water-Soluble Formazan," *J. Heterocyclic Chem.*, 25:911-914, 1988.

2 — C125 *Proceedings of the American Association for Cancer Research*, Vol. 36, p. 21, March 1995.

C154 TAKAYAMA *et al.*, "Growth Suppression of Lung Cancer by Recombinant Adenovirus-Mediated Human p53 and p21 cDNA Transfer," *Proceedings Annual Meeting, American Society of Clinical Oncology*, 16: A1597, 1997.

C164 WAHRAN *et al.*, *Tumour Biol.* 6:41-56, 1985.

C174 ZHANG *et al.*, "Generation and Identification of Recombinant Adenovirus by Liposome-Mediated Transfection and PCR? Analysis," *BioTechniques*, 15(5):868-872, 1993.

C175 ZHANG *et al.*, "High-Efficiency Gene Transfer and High-Level Expression of Wild-Type p53 in Human Lung Cancer Cells Mediated by Recombinant Adenovirus," *Cancer Gene Therapy*, 1:5-13, 1994.

The fee of \$180.00 was paid with the Supplemental Information Disclosure Statement filed on March 14, 2003, thus, no fee is required.

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Deposit Account No. **50-0665**.

Respectfully submitted,
Perkins Coie LLP

Dated: April 1, 2003

By: 

Michael J. Wise
Registration No. 34,047



34055

PATENT TRADEMARK OFFICE

Perkins Coie LLP
Patent – LA
P.O. Box 1208
Seattle, WA 98111-
1208
Phone: (310) 788-9900
Fax: (310) 788-3399